AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00817427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD- sleep extension
Description: Sleep will be increased by 2 hours each night for 3 nights
Study NCT03801200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: radiotherapy with Apatinib
Study NCT04330677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study NCT04330677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study NCT04330677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study NCT04330677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Gel
Description: Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study NCT04330677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel
Description: Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study NCT04330677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study NCT02724215 — intervention group
Intervention type: DEVICE
Intervention: Sleep Apnea Screening (Out of Center Polysomnography Device)
Study NCT01436942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes.
Study NCT00960232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 40.000 IU cholecalciferol per week for 6 months
Study NCT00960232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00407966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00218023 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
Study NCT00218023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
Study NCT00407966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00407966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT04607265 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Comparison of scar characteristics on cardiac MRI between the two groups.
Study NCT04038307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1gm
Study NCT04038307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 100ml
Study NCT01615900 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Teleconsultation / Standard consultation
Description: Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)
Study NCT05782309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavanol
Description: Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment
Study NCT05782309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
Study NCT00147472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET scan in addition to conventional CT imaging
Description: PET scans, Pre and post radiation treatment
Study NCT03960268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: interleukin 17 receptor A antagonist
Study NCT00774995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EngerixTM-B
Description: Intramuscular injection, one dose.
Study NCT00218023 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency management (CM)
Description: Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
Study NCT00218023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
Study NCT02472431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracavernosal administration of autologous ADRC
Description: Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
Study NCT02472431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study NCT02472431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study NCT03531684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MMFS-205-SR
Description: Twice daily, oral, 500 mg tablets
Study NCT03531684 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, oral
Study NCT05071235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG1 (LLLT group 1)
Description: Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².
Study NCT05071235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG2 (LLLT group 2)
Description: Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².
Study NCT05071235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG3 (LLLT group 3)
Description: Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².
Study NCT05071235 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CG (control group)
Description: Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.
Study NCT05071235 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study NCT05071235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study NCT00359073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg everyday
Study NCT00359073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: like placebo
Study NCT02164084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204
Description: SB204 Gel with hydrogel
Study NCT02164084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel with hydrogel
Study NCT00218023 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
Study NCT02763007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alogliptin+pioglitazone
Description: alogliptin and pioglitazone add on metformin
Study NCT02763007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alogliptin
Description: nesina add on metformin
Study NCT02763007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: actos add on metformin
Study NCT00656422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin Levemir
Description: The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
Study NCT00656422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin Lantus
Description: The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
Study NCT01015534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT01015534 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain irradiation
Study NCT01015534 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain irradiation
Study NCT01698463 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes
Description: The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
Study NCT03604224 — intervention group
Intervention type: DRUG
Intervention: Canagliflozin 300 mg
Description: Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
Study NCT02998645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
Study NCT02998645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained
Study NCT00839488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole 40 mg iv
Description: pnatoprazole 40 mg iv qd
Study NCT04865757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space Flap
Description: A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
Study NCT04661345 — intervention group
Intervention type: OTHER
Intervention: Proteomic analysis of synovial fluids
Description: Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
Study NCT04366648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology
Study NCT04366648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology
Study NCT02823782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI and neuropsychological assessment planned for the study for patient and volunteers
Study NCT02823782 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI and neuropsychological assessment planned for the study for patient and volunteers
Study NCT02823782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Study NCT02823782 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological assessment
Study NCT04661345 — intervention group
Intervention type: OTHER
Intervention: Proteomic analysis of the isolated coagulase-negative Staphylococci
Description: Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
Study NCT03548584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablets
Study NCT03548584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT02533921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary outpatient palliative care
Description: Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
Study NCT02533921 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Usual care defined as including both a PCP and neurologist
Study NCT03865290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Oral Ondansetron 8 mg
Study NCT01728376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Study NCT01728376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Study NCT03865290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matched placebo
Study NCT02041598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHW Intervention
Description: 5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
Study NCT01532466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
Study NCT01177735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
Study NCT03992326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIL
Description: Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
Study NCT03992326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study NCT03992326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study NCT02944344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Conversations
Description: The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
Study NCT03992326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study NCT03992326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
Study NCT02594722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-cycling
Description: Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
Study NCT02944344 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Four Conversations
Description: The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
Study NCT02594722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Classic cycloergometer
Description: Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
Study NCT04311034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
Study NCT04216134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT04216134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 68GA-PSMA-11 PET
Study NCT05492084 — intervention group
Intervention type: OTHER
Intervention: without Intervention
Description: without Intervention
Study NCT02753647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab